Coulter Pharmaceutical, Inc.
Records under this name other than patents Coulter Pharmaceutical, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
Back to Coulter Pharmaceutical, Inc.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,816,317 | Tripeptide prodrug compounds Formerly held Lapsed on the fee record Ended Oct 19, 2022 · USPTO record | Lapsed on the fee record | Ended Oct 19, 2022 | USPTO record |
| US 7,214,663 | Tripeptide prodrug compounds Formerly held Term ended Term ended Sep 4, 2022 · USPTO record | Term ended | Term ended Sep 4, 2022 | USPTO record |
| US 7,668,662 | Patient-Specific Dosimetry Formerly held Term ended Term ended Apr 12, 2022 · Medium confidence | Term ended | Term ended Apr 12, 2022 | Medium confidence |
| US 7,696,313 | Prodrug compounds with isoleucine Formerly held Term ended Term ended Jun 11, 2021 · USPTO record | Term ended | Term ended Jun 11, 2021 | USPTO record |
| US 8,034,787 | Enzyme-cleavable prodrug compounds Formerly held Term ended Term ended Jun 10, 2021 · USPTO record | Term ended | Term ended Jun 10, 2021 | USPTO record |
| US 7,425,541 | Enzyme-cleavable prodrug compounds Formerly held Lapsed on the fee record Ended Sep 16, 2020 · USPTO record | Lapsed on the fee record | Ended Sep 16, 2020 | USPTO record |
| US 6,287,537 | Radioimmunotherapy of lymphoma using anti-CD20 antibodies Formerly held Term ended Term ended May 29, 2018 · USPTO record | Term ended | Term ended May 29, 2018 | USPTO record |
| US 6,090,365 | Radioimmunotherapy of lymphoma using anti-CD20 antibodies Formerly held Term ended Term ended Nov 18, 2017 · USPTO record | Term ended | Term ended Nov 18, 2017 | USPTO record |
| US 6,338,835 | Radioprotectant for peptides labeled with radioisotope Formerly held Term ended Ended no later than Aug 21, 2017 · USPTO record | Term ended | Ended no later than Aug 21, 2017 | USPTO record |
| US 6,015,542 | Radioimmunotherapy of lymphoma using anti-CD20 antibodies Formerly held Term ended Term ended Sep 10, 2016 · USPTO record | Term ended | Term ended Sep 10, 2016 | USPTO record |